Cargando…

Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience

BACKGROUND: Vedolizumab, which is a monoclonal antibody that selectively binds to α4β7 integrin in the gastrointestinal system, may be an effective and safe treatment alternative in those with anti-tumor necrosis factor-resistant inflammatory bowel disease. METHODS: Patients administered vedolizumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Erdoğan, Çağdaş, Yeşil, Bayram, Bacaksız, Ferhat, Arı, Derya, Gökbulut, Volkan, Yüksel, Mahmut, Özin, Yasemin Özderin, Kayaçetin, Ertuğrul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Turkish Society of Gastroenterology 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623212/ https://www.ncbi.nlm.nih.gov/pubmed/35946879 http://dx.doi.org/10.5152/tjg.2022.21684

Ejemplares similares

Relationship Among Helicobacter Pylori, Lower Esophagus Sphincter Pressure, and Gastroesophageal Reflux: A Single-Center Experience
por: Bacaksiz, Ferhat, et al.
Publicado: (2022)

Is Oxidative Stress Associated with Activation and Pathogenesis of Inflammatory Bowel Disease?
por: Yuksel, Mahmut, et al.
Publicado: (2017)

Crohn’s disease in the elderly: Clinical presentation and manifestations from a tertiary referral center in Turkey
por: Saygili, Fatih, et al.
Publicado: (2017)

Thiol/disulphide homeostasis in celiac disease
por: Kaplan, Mustafa, et al.
Publicado: (2017)

The Role of Oxidative Stress in the Etiopathogenesis of Gluten-sensitive Enteropathy Disease
por: Kaplan, Mustafa, et al.
Publicado: (2017)

Platelet-to-lymphocyte Ratio and Neutrophil-to-lymphocyte Ratio Predict Mucosal Disease Severity in Ulcerative Colitis
por: Akpinar, Muhammet Yener, et al.
Publicado: (2018)

The Relationship Between Achalasia and Esophageal Cancer: The Experience of a Tertiary Center
por: Öztürk, Ömer, et al.
Publicado: (2022)

Evaluation of non-gastric upper gastrointestinal system polyps: an epidemiological assessment
por: Erdoğan, Çağdaş, et al.
Publicado: (2023)

Tissue quantitative RT–PCR test for diagnostic significance of cytomegalovirus infection in patients with inflammatory bowel disease and treatment response: Cytomegalovirus infection in patients with inflammatory bowel disease
por: Ozdemir, Burcu, et al.
Publicado: (2023)

The role of the PLR–NLR combination in the prediction of the presence of Helicobacter pylori and its associated complications
por: Kaplan, Mustafa, et al.
Publicado: (2018)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
por: Crooks, Benjamin, et al.
Publicado: (2020)

Effect of obesity on vedolizumab response in inflammatory bowel disease
por: Levine, Louis J., et al.
Publicado: (2022)

Pneumatic Dilation in Geriatric Achalasia Patients
por: Tenlik, İlyas, et al.
Publicado: (2023)

Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab
por: Krupka, Niklas, et al.
Publicado: (2014)

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
por: Fleisher, Mark, et al.
Publicado: (2018)

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Vedolizumab Is Safe in Elderly Veteran Patients With Inflammatory Bowel Disease
por: Leung, Kenneth, et al.
Publicado: (2021)

Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases
por: Scarozza, Patrizio, et al.
Publicado: (2020)

Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
por: Lynch, Kate D., et al.
Publicado: (2020)

The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
por: Abraham, Bincy P., et al.
Publicado: (2023)

Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience
por: Oršić Frič, Vlasta, et al.
Publicado: (2023)

A New Marker to Determine Prognosis of Acute Pancreatitis: PLR and NLR Combination
por: Kaplan, Mustafa, et al.
Publicado: (2018)

Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases
por: Yarur, Andres J., et al.
Publicado: (2020)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
por: Saad Alshahrani, Abdulaziz, et al.
Publicado: (2023)

Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease
por: Singh, Harmanjit, et al.
Publicado: (2016)

Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases
por: Bertani, Lorenzo, et al.
Publicado: (2020)

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
por: Vaughn, Byron P., et al.
Publicado: (2020)

Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases
por: Luzentales-Simpson, Matthew, et al.
Publicado: (2021)

Vedolizumab Immunogenicity With Long‐Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease
por: Wyant, Timothy, et al.
Publicado: (2021)

Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review
por: Fang, Shengbo, et al.
Publicado: (2022)

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
por: Choi, Myeong Geun, et al.
Publicado: (2022)

The Effect of Vedolizumab on Spondyloarthritis Symptoms in a Cohort of Inflammatory Bowel Disease Patients
por: Huseynzada, Sinakhanım, et al.
Publicado: (2023)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

A Single-Center Study of Long-Term Effectiveness of Vedolizumab in Anti-TNF Refractory Pediatric Inflammatory Bowel Disease
por: Patel, Halee, et al.
Publicado: (2022)

Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence
por: Scribano, Maria Lia
Publicado: (2018)

Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
por: Rath, Timo, et al.
Publicado: (2018)

Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions
por: Ward, Mark G., et al.
Publicado: (2018)

Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview
por: Pouillon, Lieven, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r7djtg5vsf0ojs57lrj2ip2u56